Page 8 - Haematologica Vol. 109 - July 2024

2277 Characterization of zanubrutinib safety and tolerability profile and comparison with ibrutinib safety profile in patients with B-cell malignancies: post hoc analysis of a large clinical trial safety database J.R. Brown et al.
https://doi.org/10.3324/haematol.2023.283846
2284 Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib- intolerant patients with B-cell malignancies
L. Xu et al.
https://doi.org/10.3324/haematol.2023.283861
2290 Proteogenomic profiling uncovers differential therapeutic vulnerabilities between TCF3::PBX1 and TCF3::HLF translocated B-cell acute lymphoblastic leukemia
L. Blümel et al.
https://doi.org/10.3324/haematol.2023.283928
2297 Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study
E. Iannitto et al.
https://doi.org/10.3324/haematol.2023.284109
2303 Cytomegalovirus Triplex vaccine in pediatric hematopoietic stem cell transplant patients at high risk for cytomegalovirus complications: evaluation of vaccine safety, immunogenicity and impact on viremia requiring antivirals
C. La Rosa et al.
https://doi.org/10.3324/haematol.2023.284256
2309 Efficacy of DYRK1A inhibitors in novel models of Down syndrome acute lymphoblastic leukemia S.L. Carey-Smith et al.
https://doi.org/10.3324/haematol.2023.284271
2316 Selection of dormant cells during treatment of T-lineage lymphoblastic leukemia and CREB as a therapeutic target
D. Masic et al. https://doi.org/10.3324/haematol.2023.284335
2321 Mycophenolate mofetil is associated with inferior overall survival in cytomegalovirus-seropositive patients with acute myeloid leukemia undergoing hematopoietic cell transplantation
R.M. Saliba et al.
https://doi.org/10.3324/haematol.2023.284501
2326 Validation of LymphGen classification on a 400-gene clinical next-generation sequencing panel in diffuse large B-cell lymphoma: real-world experience from a cancer center
M.L. Zhu et al.
https://doi.org/10.3324/haematol.2023.284565
2331 Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN study
F.H. Schjesvold et al.
https://doi.org/10.3324/haematol.2023.284635
2337 Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma
M.V. Mateos et al.
https://doi.org/10.3324/haematol.2023.284694
2341 Evidence for a cytoplasmic proplatelet promoting factor that triggers platelet production J.E. Italiano et al.
https://doi.org/10.3324/haematol.2023.284755
Haematologica | 109 July 2024
IV